Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives (1)
- Extensive variability, pregnancy is not a dichotomous covariate
- Pregnancy pharmacokinetics and pharmacodynamics
- Learning objectives (2)
- Pregnancy-related physiological changes (1)
- Pregnancy-related physiological changes: liver and gastro-intestinal
- Pregnancy-related physiological changes: kidneys
- Pregnancy-related physiological changes (2)
- Pregnancy-related physiological changes: impact on PK
- Clinical relevance for amoxicillin
- Clinical relevance for lithium
- Clinical relevance for acetaminophen/paracetamol
- Clinical relevance for acetaminophen/paracetamol (glucuronidation)
- Clinical relevance for CYP and PB
- Pregnancy-related pharmacodynamics
- Placenta-related drug transfer: beyond passive diffusion (1)
- Placenta-related drug transfer: beyond passive diffusion (2)
- Clinical relevance for opioids
- Placenta-related drug transfer: clinical examples
- Placenta-related drug transfer: clinical relevance and teratology
- Lactation-related drug transfer (1)
- Lactation-related drug transfer (2)
- Lactation-related drug transfer follows pregnancy-related exposure: AEDs
- Lactation-related drug transfer (3)
- Lactation-related drug transfer (4)
- Clinical lactation studies
- How to integrate pregnancy or lactation-related changes (1)
- How to integrate pregnancy or lactation-related changes (2)
- How to integrate pregnancy or lactation-related changes (3)
- How to convert to guidance and practices: impact needed (1)
- How to convert to guidance and practices: impact needed (2)
- How to convert to guidance and practices: impact needed (3)
- How to convert to guidance and practices: impact needed (4)
- How to convert to guidance and practices: impact needed (5)
- Suggested reading
- Learning objectives (3)
- Acknowledgements
Topics Covered
- Clinical pharmacology during pregnancy and lactation
- Pharmacokinetics and pharmacodynamics during pregnancy
- Pregnancy-related physiological changes
- Placenta-related drug transfer
- Lactation-related drug transfer
- Guidance and practices
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Allegaert, K. (2024, August 29). Clinical pharmacology during pregnancy and lactation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/BLSG9492.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose. However, off label use of medicines is discussed.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to this lecture on
clinical pharmacology during
pregnancy and lactation.
I'm Karel Allegaert.
I'm a clinician-researcher
working
at Rotterdam University
as well as KU Leuven.
0:14
The overarching learning
objective of this lecture is to
highlight the specific
characteristics
related to both pharmacokinetics
and pharmacodynamics and related
to these pharmacodynamics
also aspects related
to safety for mother, fetus
and potentially
lactating infant.
As we all know, a given dose
will result in a
given concentration
in a compartment in the body;
most commonly studied is
obviously the blood compartment.
This concentration
will subsequently
result in a given effect
and that's what makes
a difference between
pharmacokinetics and
pharmacodynamics.
Obviously, pregnancy
in itself will have
a major impact on drug handling
and potentially also
on drug effects.
This is the focus or
the learning objective
of this lecture.
1:01
As I already somewhat alluded to
there is extensive variability.
This means that the
pharmacokinetics and/or
pharmacodynamics may change
significantly
throughout pregnancy.
An important message hereby is
that pregnancy in itself is
not a dichotomous covariant.
As for instance,
consecutive trimesters of
pregnancy may have
different impacts
on drug handling
or drug effects.
To somewhat further
extent, the idea
initially raised on children and
their specific characteristics
to study drugs.
The child is not just a small
adult and the newborn is not
just a small child
along the same way
pregnant woman is not just
a woman with a big belly.